AdvertiseDonate
Tuesday, November 17, 2026
City news, clearly told.
Hot Report Digest · 393 State Street, Salem, OR 97301
News · Loma Linda

13.2 Months: New Pill Extends Life for Pancreatic Cancer Patients

The FDA-approved treatment, daraxonrasib, shows a median survival increase of over six months compared to standard chemotherapy in a phase 3 trial.

By Luis Fernandez ·

Illustration for: 13.2 Months: New Pill Extends Life for Pancreatic Cancer Patients
Illustration generated for this article, not a news photograph.

Patients with metastatic pancreatic cancer who take the new daily pill daraxonrasib lived a median of 13.2 months in a recent clinical trial, compared with 6.7 months for those receiving chemotherapy. The U.S. Food and Drug Administration approved the drug roughly two months ago, marking a shift in how one of the most aggressive cancers is treated.

Pancreatic cancer remains a leading cause of death in the United States. The American Cancer Society estimates that nearly 53,000 Americans will die from the disease in 2026. The five-year relative survival rate for all stages is approximately 13%. Mark Reeves, director of the Loma Linda University Cancer Center, noted that the disease is often diagnosed late because it produces few early symptoms and spreads quickly.

Historically, doctors struggled to treat the disease because of RAS, a molecule that drives tumor growth. Reeves described RAS as long considered undruggable because existing drugs could not effectively impact its many mutations. Daraxonrasib addresses this by binding to the active form of RAS, thereby blocking the signals that fuel cancer growth.

The approval is based on a phase 3 clinical trial involving 500 patients with previously treated metastatic pancreatic cancer. In that study, patients taking daraxonrasib experienced a median survival of 13.2 months. The control group, which received chemotherapy, had a median survival of 6.7 months. Reeves stated that this increase in outcome could change both the longevity and quality of life for patients.

Daraxonrasib is approved for adults with metastatic pancreatic cancer who have already received at least one other systemic treatment or who are not candidates for combination drug therapy. Unlike chemotherapy, which is administered via intravenous infusion, the new treatment is a daily oral pill. Trial data indicated that patients taking the pill experienced fewer severe side effects than those on chemotherapy.

Loma Linda University Health is using Pancreatic Cancer Awareness Month to inform the public about the new option. The center is directing patients to its website or phone line to learn about eligibility and available resources for those affected by the disease.

More News · Report a business · Got a Story?

Get Hot Report Digest in your inboxCity news, clearly told. Free, a few times a week, unsubscribe any time.

Related stories

Get Hot Report Digest in your inboxCity news, clearly told. Free, a few times a week, unsubscribe any time.